世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000035073

筋弛緩薬市場-規模、シェア、動向分析レポート、予測2023-2030

Grand View Research Inc.

Muscle Relaxant Drugs Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2023 - 2030

発刊日 2023/05

言語英語

体裁PDF/180ページ

ライセンス/価格180ページ

0000035073

Individual
Team
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

筋弛緩薬市場規模、シェア、動向分析レポート:薬剤の種類別(骨格筋弛緩薬、顔面筋弛緩薬)、投与経路別、流通チャネル別、地域別、およびセグメント予測、2023〜2030

レポートの概要
世界の筋弛緩薬市場規模は2022年に37億4,000万ドルと評価され、2023年から2030年までに4.38%のCAGRで成長すると予想されます。「筋弛緩薬」という用語は通常、中枢神経系 (CNS) に作用して骨格筋を弛緩させる薬剤を表すために使用されます。これらの薬剤は、捻挫、挫傷、またはその他の種類の筋肉損傷に伴う不快感や痛みを軽減するために頻繁に処方されます。世界の筋弛緩薬市場は非常に競争が激しく細分化されており、いくつかの主要企業が市場シェアを争っています。この分野は主に、筋肉痛やけいれんの有病率の高まり、効果的な治療オプションに対する需要の増加、主要メーカーによる戦略的取り組みの強化などが推進要因になっています。

レポート詳細

目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Growing geriatric population
3.4.2. Increasing prevalence of musculoskeletal disorders
3.5. Market Restraint Analysis
3.5.1. Adverse effects of muscle relaxants
3.6. Penetration and Growth Prospect Mapping 2022
3.7. Business Environment Analysis
3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.7.2. Porter’s Five Forces Analysis
3.8. COVID - 19 Impact Analysis

Chapter 4. Drug Type Business Analysis
4.1. Muscle relaxant drugs market: Drug Type Movement Analysis
4.2. Skeletal Muscle Relaxant Drugs
4.2.1. Skeletal Muscle Relaxant Market, 2018 - 2030 (USD Million)
4.3. Facial Muscle Relaxant Drugs
4.3.1. Facial Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
4.4. Neuromuscular Blocking Agents
4.4.1. Neuromuscular Blocking Agents Market, 2018 - 2030 (USD Million)

Chapter 5. Route of Administration Business Analysis
5.1. Muscle relaxant drugs market: Route of Administration Movement Analysis
5.2. Oral Market, 2018 - 2030 (USD Million)
5.2.1. Oral Market, 2018 - 2030 (USD Million)
5.3. Injectable
5.3.1. Injectable Market, 2018 - 2030 (USD Million)
5.4. Others
5.4.1. Others Market ,2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis
6.1. Muscle relaxant drugs market: Distribution Channel Movement Analysis
6.2. Hospital Pharmacy
6.2.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
6.3. Retail Pharmacy
6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
6.4. Online Pharmacy
6.4.1. Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis
7.1. Muscle Relaxant Drugs Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. SWOT Analysis
7.2.2. North America Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.2.3. U.S.
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. Reimbursement Scenario
7.2.3.6. U.S. Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.2.4. Canada
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Competitive Scenario
7.2.4.4. Regulatory Framework
7.2.4.5. Reimbursement Scenario
7.2.4.6. Canada Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. SWOT Analysis
7.3.2. Europe Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Reimbursement Scenario
7.3.3.6. Germany Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.4. UK
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Reimbursement Scenario
7.3.4.6. UK Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.5. France
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Reimbursement Scenario
7.3.5.6. France Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Reimbursement Scenario
7.3.6.6. Italy Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.7. Spain
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Reimbursement Scenario
7.3.7.6. Spain Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.8. Denmark
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Reimbursement Scenario
7.3.8.6. Denmark Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.9. Sweden
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Reimbursement Scenario
7.3.9.6. Sweden Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.10. Norway
7.3.10.1. Key Country Dynamics
7.3.10.2. Target Disease Prevalence
7.3.10.3. Competitive Scenario
7.3.10.4. Regulatory Framework
7.3.10.5. Reimbursement Scenario
7.3.10.6. Norway Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. SWOT Analysis
7.4.2. Asia Pacific Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Reimbursement Scenario
7.4.3.6. Japan Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.4.4. China
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. Reimbursement Scenario
7.4.4.6. China Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.4.5. India
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Reimbursement Scenario
7.4.5.6. India Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.4.6. South Korea
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Reimbursement Scenario
7.4.6.6. South Korea Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.4.7. Australia
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Reimbursement Scenario
7.4.7.6. Australia Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.4.8. Thailand
7.4.8.1. Key Country Dynamics
7.4.8.2. Target Disease Prevalence
7.4.8.3. Competitive Scenario
7.4.8.4. Regulatory Framework
7.4.8.5. Reimbursement Scenario
7.4.8.6. Thailand Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. SWOT Analysis
7.5.2. Latin America Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.5.3. Brazil
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Reimbursement Scenario
7.5.3.6. Brazil Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.5.4. Mexico
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Reimbursement Scenario
7.5.4.6. Mexico Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.5.5. Argentina
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Competitive Scenario
7.5.5.4. Regulatory Framework
7.5.5.5. Reimbursement Scenario
7.5.5.6. Argentina Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. SWOT Analysis
7.6.2. MEA Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.6.3. South Africa
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Reimbursement Scenario
7.6.3.6. South Africa Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.6.4. Saudi Arabia
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. Reimbursement Scenario
7.6.4.6. Saudi Arabia Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.6.5. UAE
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Reimbursement Scenario
7.6.5.6. UAE Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.6.6. Kuwait
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Competitive Scenario
7.6.6.4. Regulatory Framework
7.6.6.5. Reimbursement Scenario
7.6.6.6. Kuwait Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2022
8.4. Company Profiles/Listing
8.4.1. Amneal Pharmaceuticals LLC
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Ipsen Biopharmaceuticals, Inc.
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Merz Pharmaceuticals, LLC.
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Par Pharmaceutical
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Endo Pharmaceuticals
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Vertical Pharmaceuticals
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Mallinckrodt
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. SteriMax
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Eisai Co., Ltd.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Teva Pharmaceuticals USA, Inc.
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives

List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 4. Global muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 5. Global muscle relaxant drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 6. Global muscle relaxant drugs market, by region, 2018 - 2030 (USD Million)
Table 7. North America muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 8. North America muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 9. North America muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 10. North America muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 11. U.S. muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 12. U.S. muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 13. U.S. muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 14. Canada muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 15. Canada muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 16. Canada muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 17. Europe muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 18. Europe muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 19. Europe muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 20. Europe muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 21. UK muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 22. UK muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 23. UK muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 24. Germany muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 25. Germany muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 26. Germany muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 27. France muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 28. France muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 29. France muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 30. Italy muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 31. Italy muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 32. Italy muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 33. Spain muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 34. Spain muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 35. Spain muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 36. Denmark muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 37. Denmark muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 38. Denmark muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 39. Sweden muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 40. Sweden muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 41. Sweden muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 42. Norway muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 43. Norway muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 44. Norway muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 45. Asia Pacific muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 46. Asia Pacific muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 47. Asia Pacific muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 48. Asia pacific muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 49. China muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 50. China muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 51. China muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 52. India muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 53. India muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 54. India muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 55. Japan muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 56. Japan muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 57. Japan muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 58. Thailand muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 59. Thailand muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 60. Thailand muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 61. Australia muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 62. Australia muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 63. Australia muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 64. South Korea muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 65. South Korea muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 66. South Korea muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 67. Latin America muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 68. Latin America muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 69. Latin America muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 70. Latin America muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 71. Brazil muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 72. Brazil muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 73. Brazil muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 74. Mexico muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 75. Mexico muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 76. Mexico muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 77. Argentina muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 78. Argentina muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 79. Argentina muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 80. Middle East & Africa muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 81. Middle East & Africa muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 82. Middle East & Africa muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 83. Middle East & Africa muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 84. South Africa muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 85. South Africa muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 86. South Africa muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 87. Saudi Arabia muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 88. Saudi Arabia muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 89. Saudi Arabia muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 90. UAE muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 91. UAE muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 92. UAE muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 93. Kuwait muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 94. Kuwait muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 95. Kuwait muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain - based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Muscle relaxant drugs, market segmentation
Fig. 8 Market snapshot, 2022
Fig. 9 Market trends & outlook
Fig. 10 Market driver relevance analysis (current & future impact)
Fig. 11 Market restraint relevance analysis (current & future impact)
Fig. 12 Market challenge relevance analysis (current & future impact)
Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 14 Porter’s five forces analysis
Fig. 15 Market penetration vs growth prospect mapping, 2022
Fig. 16 Global muscle relaxant drugs market: drug type movement analysis
Fig. 17 Global muscle relaxant drugs market, for skeletal muscle relaxant drugs, 2018 - 2030 (USD Million)
Fig. 18 Global muscle relaxant drugs market, for facial muscle relaxant drugs, 2018 - 2030 (USD Million)
Fig. 19 Global muscle relaxant drugs market, for neuromuscular blocking agents, 2018 - 2030 (USD Million)
Fig. 20 Global muscle relaxant drugs market: route of administration movement analysis
Fig. 21 Global muscle relaxant drugs market, for oral, 2018 - 2030 (USD Million)
Fig. 22 Global muscle relaxant drugs market, for injectable, 2018 - 2030 (USD Million)
Fig. 23 Global muscle relaxant drugs market: distribution channel movement analysis
Fig. 24 Global muscle relaxant drugs market, for hospital pharmacy, 2018 - 2030 (USD Million)
Fig. 25 Global muscle relaxant drugs market, for retail pharmacy, 2018 - 2030 (USD Million)
Fig. 26 Global muscle relaxant drugs market, for online pharmacy, 2018 - 2030 (USD Million)
Fig. 27 Regional marketplace: key takeaways
Fig. 28 Regional outlook, 2022 & 2030
Fig. 29 North America muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 30 U.S. muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 31 Canada muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 32 Europe muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 33 UK muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 34 Germany muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 35 France muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 36 Italy muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 37 Spain muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 38 Denmark muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 39 Sweden muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 40 Norway muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 41 Asia pacific muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 42 China muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 43 India muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 44 Japan muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 45 Thailand muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 46 Australia muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 47 South Korea muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 48 Latin America muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 49 Brazil muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 50 Mexico muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 51 Argentina muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 52 Middle East and Africa muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 53 South Africa muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 54 Saudi Arabia muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 55 UAE muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 56 Kuwait muscle relaxant drugs market, 2018 - 2030 (USD Million)

この商品のレポートナンバー

0000035073

TOP